Cargando…

Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag

BACKGROUND: The high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on (18)F-fluoro-2-deo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Maoqing, Chen, Ping, Guo, Xiuyu, Zhang, Xiaohui, Gao, Qiaoling, Zhang, Jingfeng, Zhao, Guofang, Zheng, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073355/
https://www.ncbi.nlm.nih.gov/pubmed/37014455
http://dx.doi.org/10.1186/s13550-023-00976-5
_version_ 1785019550323965952
author Jiang, Maoqing
Chen, Ping
Guo, Xiuyu
Zhang, Xiaohui
Gao, Qiaoling
Zhang, Jingfeng
Zhao, Guofang
Zheng, Jianjun
author_facet Jiang, Maoqing
Chen, Ping
Guo, Xiuyu
Zhang, Xiaohui
Gao, Qiaoling
Zhang, Jingfeng
Zhao, Guofang
Zheng, Jianjun
author_sort Jiang, Maoqing
collection PubMed
description BACKGROUND: The high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on (18)F-fluoro-2-deoxy-2-deoxyglucose ((18)F-FDG) PET/CT and serum tumor markers (STMs) to determine EGFR mutation status in male patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 121 male patients with NSCLC were analyzed between October 2019 and March 2022. All patients underwent (18)F-FDG PET/CT scan before treatment and monitored 8 STMs (cytokeratin 19 fragment [CYFRA21-1], squamous cell carcinoma-related antigen [SCC-Ag], carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], carbohydrate antigen [CA] 50, CA125, CA72-4, and ferritin). A comparison was done between EGFR mutant and wild-type patients in terms of the maximum standardized uptake value of primary tumors (pSUV(max)) and 8 STMs. We performed receiver operating characteristic (ROC) curve and multiple logistic regression analyses to determine predictors for EGFR mutation status. RESULTS: EGFR mutations were detected in 39 patients (32.2%). Compared with patients with EGFR wild-type, EGFR-mutant patients had lower concentrations of serum CYRFA21-1 (2.65 vs. 4.01, P = 0.002) and SCC-Ag (0.67 vs. 1.05, P = 0.006). No significant differences of CEA, NSE, CA 50, CA125, CA72-4 and ferritin were found between the two groups. The presence of EGFR mutations was significantly associated with low pSUV(max) (< 8.75), low serum SCC-Ag (< 0.79 ng/mL) and CYFRA21-1 (< 2.91 ng/mL) concentrations. The area under ROC curve values were 0.679, 0.655, 0.685 and 0.754, respectively, for low CYFRA21-1, SCC-Ag, pSUV(max) and the combination of these three factors. CONCLUSIONS: We demonstrated that low concentrations of CYFRA21-1 and SCC-Ag, as well as low pSUV(max), were associated with EGFR mutations, and that the combination of these factors resulted in a higher differentiation of EGFR mutation status in male patients with NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-023-00976-5.
format Online
Article
Text
id pubmed-10073355
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-100733552023-04-06 Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag Jiang, Maoqing Chen, Ping Guo, Xiuyu Zhang, Xiaohui Gao, Qiaoling Zhang, Jingfeng Zhao, Guofang Zheng, Jianjun EJNMMI Res Original Research BACKGROUND: The high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on (18)F-fluoro-2-deoxy-2-deoxyglucose ((18)F-FDG) PET/CT and serum tumor markers (STMs) to determine EGFR mutation status in male patients with non-small-cell lung cancer (NSCLC). METHODS: A total of 121 male patients with NSCLC were analyzed between October 2019 and March 2022. All patients underwent (18)F-FDG PET/CT scan before treatment and monitored 8 STMs (cytokeratin 19 fragment [CYFRA21-1], squamous cell carcinoma-related antigen [SCC-Ag], carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], carbohydrate antigen [CA] 50, CA125, CA72-4, and ferritin). A comparison was done between EGFR mutant and wild-type patients in terms of the maximum standardized uptake value of primary tumors (pSUV(max)) and 8 STMs. We performed receiver operating characteristic (ROC) curve and multiple logistic regression analyses to determine predictors for EGFR mutation status. RESULTS: EGFR mutations were detected in 39 patients (32.2%). Compared with patients with EGFR wild-type, EGFR-mutant patients had lower concentrations of serum CYRFA21-1 (2.65 vs. 4.01, P = 0.002) and SCC-Ag (0.67 vs. 1.05, P = 0.006). No significant differences of CEA, NSE, CA 50, CA125, CA72-4 and ferritin were found between the two groups. The presence of EGFR mutations was significantly associated with low pSUV(max) (< 8.75), low serum SCC-Ag (< 0.79 ng/mL) and CYFRA21-1 (< 2.91 ng/mL) concentrations. The area under ROC curve values were 0.679, 0.655, 0.685 and 0.754, respectively, for low CYFRA21-1, SCC-Ag, pSUV(max) and the combination of these three factors. CONCLUSIONS: We demonstrated that low concentrations of CYFRA21-1 and SCC-Ag, as well as low pSUV(max), were associated with EGFR mutations, and that the combination of these factors resulted in a higher differentiation of EGFR mutation status in male patients with NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-023-00976-5. Springer Berlin Heidelberg 2023-04-04 /pmc/articles/PMC10073355/ /pubmed/37014455 http://dx.doi.org/10.1186/s13550-023-00976-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Jiang, Maoqing
Chen, Ping
Guo, Xiuyu
Zhang, Xiaohui
Gao, Qiaoling
Zhang, Jingfeng
Zhao, Guofang
Zheng, Jianjun
Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag
title Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag
title_full Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag
title_fullStr Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag
title_full_unstemmed Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag
title_short Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag
title_sort identification of egfr mutation status in male patients with non-small-cell lung cancer: role of (18)f-fdg pet/ct and serum tumor markers cyfra21-1 and scc-ag
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073355/
https://www.ncbi.nlm.nih.gov/pubmed/37014455
http://dx.doi.org/10.1186/s13550-023-00976-5
work_keys_str_mv AT jiangmaoqing identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag
AT chenping identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag
AT guoxiuyu identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag
AT zhangxiaohui identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag
AT gaoqiaoling identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag
AT zhangjingfeng identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag
AT zhaoguofang identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag
AT zhengjianjun identificationofegfrmutationstatusinmalepatientswithnonsmallcelllungcancerroleof18ffdgpetctandserumtumormarkerscyfra211andsccag